1. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014; 12:265–273.e1.
2. Pei W, Zhou H, Chen J, Liu Q. Treatment and prognosis analysis of 64 cases with anorectal malignant melanoma. Zhonghua Wei Chang Wai Ke Za Zhi. 2016; 19:1305–1308.
3. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119.
4. Garg SK, Loftus EV Jr. Risk of cancer in inflammatory bowel disease: going up, going down, or still the same? Curr Opin Gastroenterol. 2016; 32:274–281.
5. Shah SB, Pickham D, Araya H, et al. Prevalence of anal dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015; 13:1955–1961.e1.
6. Slesser AA, Bhangu A, Bower M, Goldin R, Tekkis PP. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol. 2013; 22:230–237.
7. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 12:210–218.
8. Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014; 20:9872–9881.
9. Abbas AM, Almukhtar RM, Loftus EV Jr, Lichtenstein GR, Khan N. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol. 2014; 109:1781–1793.
10. Cheung MC, Perez EA, Molina MA, et al. Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg. 2008; 12:731–738.